Skip to main content
Lincoln Pharmaceuticals ltd. logo

Lincoln Pharmaceuticals ltd. — Investor Relations & Filings

Ticker · LINCOLN ISIN · INE405C01035 LEI · 3358004B6OBJNW8RTT10 BSE.NS Manufacturing
Open in API
Filings indexed 446 across all filing types
Latest filing 2026-05-18 Regulatory Filings
Country IN India
Listing BSE.NS LINCOLN

About Lincoln Pharmaceuticals ltd.

https://www.lincolnpharma.com/

Lincoln Pharmaceuticals Ltd. focuses on the development, manufacturing, and marketing of a diverse range of therapeutic formulations. The organization operates advanced manufacturing facilities certified by international standards, including WHO-GMP. Its portfolio spans multiple areas such as anti-infectives, cardiovascular, gastrointestinal, respiratory, and pain management. The company is recognized for its research and development initiatives, particularly in Novel Drug Delivery Systems (NDDS). Key offerings include specialized treatments for tinnitus and a wide array of formulations in dosage forms like tablets, capsules, liquid orals, and injectables. It maintains a significant global footprint, supplying products to numerous international markets across Africa, Southeast Asia, and Latin America, supported by a robust distribution network for its extensive healthcare catalog.

Recent filings

Filing Released Lang Actions
Meeting of the Board of Directors is scheduled to be held on May 28, 2026 to consider and approve Audited Financial Results of the Company and recommendation of Dividend on equity shares ....
Regulatory Filings Classification · 89% confidence The document is a formal notice under SEBI LODR Regulation 29 to the stock exchanges, informing investors of a forthcoming Board of Directors meeting to approve audited financial results and consider dividends. It does not itself contain the financial results (so it is not an earnings release or financial report), nor is it a change in board composition. It is a routine regulatory announcement. No specific category covers “Board meeting notice,” so it falls under the general regulatory filings catch-all. Thus RNS is appropriate.
2026-05-18 English
Lincoln Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2026 ,inter alia, to consider and approve Audited (standalone ....
Board/Management Information Classification · 95% confidence The document is a stock exchange submission under SEBI LODR Regulation 29 notifying an upcoming Board of Directors meeting date to consider and approve financial results and dividend. It does not contain the results themselves, but is an intimation of a board meeting. This fits the Board/Management Information category.
2026-05-18 English
Annual Secretarial Compliance Report for the financial year ended March 31, 2026.
Regulatory Filings Classification · 85% confidence The document is a Secretarial Compliance Report submitted under Regulation 24A of SEBI (LODR) Regulations, 2015 by the Company Secretary to the stock exchanges. It is a statutory compliance certificate rather than a financial report (e.g., annual or interim report), management discussion, earnings release, or proxy materials. It is also not merely an announcement that a report is available (it includes the full compliance content). Therefore it best fits the catch-all category for general regulatory filings and compliance documents: Regulatory Filings (RNS).
2026-05-12 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document primarily consists of a notice from Lincoln Pharmaceuticals Ltd. regarding the transfer of equity shares to the Investor Education Protection Fund Authority (IEPF Authority) due to unclaimed dividends, citing compliance with the Companies Act, 2013 and SEBI regulations. This is a regulatory announcement informing shareholders about the transfer process and inviting claims. There is no financial data, management discussion, or detailed report content. The rest of the document contains repetitive and unrelated text fragments that do not pertain to any financial report or detailed filing. The document is essentially an official regulatory announcement related to shareholder rights and compliance, not a financial report or detailed filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2026-05-08 English
Copies of Newspaper Advertisement as required under Rule 6 of IEPF Authority (Accounting, Audit, Transfer and Refund)Rules, 2016 and amendments thereof.
Regulatory Filings Classification · 95% confidence The document is a letter from Lincoln Pharmaceuticals Ltd. addressed to stock exchanges regarding a newspaper advertisement for the transfer of equity shares to the Investor Education Protection Fund Authority (IEPF Authority). It references compliance with the Companies Act, 2013 and SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, and mentions a notice published in the newspaper inviting shareholders to claim unclaimed dividends before shares are transferred to the IEPF Authority. The document is essentially an announcement of a regulatory compliance action and a published notice, not a financial report or detailed filing. It does not contain financial statements, management discussion, or detailed financial data. The document length is about 7,316 characters, which is relatively short and consistent with an announcement. Therefore, this document fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance communication.
2026-05-08 English
Reply to Clarification- Financial results
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India Ltd. providing clarification regarding previously submitted quarterly financial results for the quarter ended September 2025. It explains why the standalone and consolidated profit and loss figures are identical due to no transactions in the subsidiary. The document is short (2072 characters) and serves as a clarification or regulatory communication rather than the financial report itself. It does not contain actual financial statements or substantive financial data but rather addresses a regulatory observation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2026-04-08 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.